However, cardioversion is associated with periprocedural thromboembolic events. Furthermore, AF symptoms can resolve spontaneously within 24 hours in many patients with new-onset AF. [2] [3] [4] Rates of spontaneous conversion range from 50% 4 to 71% 3 in recent-onset AF, and shorter duration of symptoms is a significant predictor of spontaneous conversion. 5, 6 The ability to identify patients with a high probability of spontaneous conversion is important, and could be used in the decision to postpone cardioversion and avoid the risks associated with the procedure.
ENSURE-AF is the largest prospective randomized clinical trial of anticoagulation in patients undergoing electrical cardioversion of non-valvular AF; the study demonstrated similar efficacy and safety of the oral factor Xa inhibitor edoxaban versus enoxaparin-warfarin. 7 We performed an ancillary analysis using the ENSURE-AF data to determine the incidence of spontaneous conversion. Our aim was, first, to compare the data from patients with spontaneous conversion to those with non-spontaneous conversion; second, to describe the characteristics and outcomes of patients with spontaneous conversion; and third, to identify independent predictors of spontaneous conversion, to more accurately identify patients who are likely to undergo spontaneous conversion to sinus rhythm.
Methods
The design of the ENSURE-AF study (ClinicalTrials.gov, number NCT02072434) has been described elsewhere. 7, 8 The study design, and the distribution of spontaneous conversion in the 2 groups and according to use of transesophageal echocardiography (TEE), is illustrated in Figure 1 .
In both treatment groups, cardioversion had to be performed within 3 days of randomization (TEE and cardioversion could be performed on the same day). All patients were followed for safety for 30 days after completing or discontinuing the treatment.
Patients with spontaneous conversion in the preprocedural period (confirmed by an electrocardiogram recording of sinus rhythm, assessed by the investigator) needed to complete 28 days of treatment from the day that spontaneous conversion was noted, and completed 30 days of follow-up.
The primary efficacy endpoint was the composite of stroke, systemic embolic event, myocardial infarction, or cardiovascular mortality occurring from randomization to the end of follow-up. The primary safety endpoint was the composite endpoint of major and clinically relevant non-major bleeding from the first administration of study drug to the end of treatment.
The primary efficacy analysis was done in the intention-to-treat population (defined as all patients enrolled in the study and randomly assigned. 7, 8 The primary safety analysis included all patients who took at least one dose of study drug (safety population). Efficacy and safety outcomes were compared between patients with spontaneous conversion and patients with nonspontaneous conversion.
Continuous variables are presented as mean ± standard deviation (SD). Categorical variables are presented as numbers and percentages of patients in each category. Data were compared using one-way analysis of variance for numerical data and Fisher's exact test for categorical data.
Logistic regression was used to determine clinical and demographic characteristics (age, creatinine clearance, hemoglobin value, CHA 2 DS 2 -VASc score and its components, congestive heart failure, hypertension, diabetes mellitus, prior stroke or transient ischemic attack, coronary artery disease, edoxaban dose-reduction factor, use of TEE) and prior treatment (calcium-channel blockers, beta-blockers, antiarrhythmic drugs, digoxin, renin-angiotensin system blockers, cardioversion procedure) associated with spontaneous conversion. Odds ratios and 95% confidence intervals were calculated.
Statistical analysis was performed using SAS software (SAS Institute, Cary, NC, USA).
Results
Between 25 March 2014 and 28 October 2015, 2199 patients were enrolled and randomly assigned to receive edoxaban (n = 1095) or enoxaparin-warfarin (n = 1104). Of these patients, 167 (7.6%) underwent spontaneous conversion before scheduled electrical cardioversion, 72 patients (6.6%) in the edoxaban arm and 95 (8.6%) in the enoxaparin-warfarin arm. The baseline characteristics of the patients with spontaneous conversion or nonspontaneous conversion are detailed in Table I . Mean age was 63.9 ± 10.3 years in patients with spontaneous conversion and 64.3 ± 10.6 years in patients with nonspontaneous conversion. Mean CHA 2 DS 2 -VASc scores were 2.6 ± 1.5 and 2.6 ± 1.4, respectively. History of paroxysmal AF was more frequent in the spontaneous conversion group (P b .001), whereas use of beta-blockers was more frequent in the non-spontaneous conversion group (P = .037). The TEE group was less prevalent in the spontaneous conversion group (P b .001).
Forty-seven of 1147 (4.0%) patients underwent spontaneous conversion in the TEE-guided group versus 120 of 1002 (11.8%) patients in the non-TEE-guided group. In a multivariable logistic regression analysis, history of paroxysmal AF (P b .001) was associated with spontaneous conversion, whereas advancing age (P = .001), baseline creatinine clearance (P = .0027), and use of TEE (P b .0001) were associated with a reduced likelihood of spontaneous conversion (Table II) .
None of the patients with spontaneous conversion had a stroke, systemic embolic event, myocardial infarction or cardiovascular death, or had an episode of on-treatment major or major and clinically relevant non-major bleeding.
Discussion ENSURE-AF is the largest prospective, multicenter, randomized study in patients with AF undergoing planned electrical cardioversion. In this post-hoc analysis from ENSURE-AF, 7.6% of patients underwent spontaneous conversion, with a higher rate among the non-TEEguided group. History of paroxysmal AF was the only independent predictor of spontaneous conversion. Spontaneous conversion was not associated with thromboembolic or bleeding events.
An ancillary analysis of the multicenter, prospective Assessment of Cardioversion Using Transesophageal Echocardiography (ACUTE) trial, in which TEE-guided treatment was compared with conventional anticoagulation treatment for the management of AF, reported that 167 of 1041 (16%) patients with AF of N2 days' duration underwent spontaneous conversion, with twice as many of those who converted in the conventional versus the TEE-guided group (21% vs. 11%; P b .001). 9 The ACUTE II 10 pilot trial, which compared the safety and efficacy of enoxaparin with unfractionated heparin (and was interrupted prematurely because of low enrollment and event rates) reported that 7 of 76 (9.2%) patients in the enoxaparin group and 13 of 79 (16.5%) in the unfractionated heparin group experienced spontaneous conversion. Similar to our study, the rate of spontaneous conversion in the X-VeRT study, which compared rivaroxaban with vitamin K antagonists for cardioversion in AF in patients with AF of N48 hours' or unknown duration, was 7.7%. 11 These differences in reported rates of spontaneous cardioversion are likely to reflect the duration of AF, which was shorter in ACUTE.
Given the periprocedural risks of thromboembolism, identifying predictors of spontaneous conversion is important for the management of patients being considered for electrical cardioversion. The ongoing ACWAS trial, 12 an investigator-initiated randomized noninferiority trial, will compare a watch-and-wait approach with the standard of care cardioversion in patients with recent-onset symptomatic AF in the emergency department without urgent need for cardioversion.
Limitations
Despite the large size of the trial, our analysis did not consider some of the predictors of spontaneous conversion reported in the ACUTE trial, 3 such as New York Heart Association class, left-atrial size, and left-atrial spontaneous echo contrast. Stunning and functional recovery of the left atrium and its appendage are strongly determined by the duration of AF, and we could not assess delay between occurrence of AF and spontaneous conversion, or the TEE parameters in the TEE group. This study was limited to patients with AF of least 48 hours' and b12 months' duration and may not be applicable to patients with a shorter or longer history of AF.
Conclusions
In this contemporary study of patients with AF planned for electrical cardioversion, 7.6% of our population underwent spontaneous conversion, with a higher rate among the non-TEE-guided group. History of paroxysmal AF was the only independent predictor of spontaneous conversion. Spontaneous conversion to sinus rhythm was not associated with thromboembolic or bleeding events.
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